minitjshah's profile picture. MBBS, MD, DM Medical Oncology (Gold Medalist), Assistant Professor, Solid Tumor, Tata Memorial Centre, Mumbai, India.

Minit Shah

@minitjshah

MBBS, MD, DM Medical Oncology (Gold Medalist), Assistant Professor, Solid Tumor, Tata Memorial Centre, Mumbai, India.

Minit Shah сделал(а) репост

Lower-dose abiraterone demonstrated comparable efficacy to standard-dose abiraterone, positioning itself as a viable alternative for patients with mCRPC, according to data presented at #ASCO25. | @minitjshah urologytimes.com/view/lower-dos…


Minit Shah сделал(а) репост

Big congrats to Dr. Sudeep Gupta & TMH Breast DMG team! New JCO Global Oncology study of 1,004 HER2+ BC patients on NAT. ✅ pCR: 22.5% → OS 87.3% vs 64.7% (no pCR) 💉 Trastuzumab >24w = best OS (80.5%) ⚠️ Baseline tumor burden prognostic even after pCR Access + duration…


Minit Shah сделал(а) репост

Indian real-world data (@JCOGO_ASCO) confirms trastuzumab before/after surgery + maintenance enhances survival in HER2-positive breast cancer, esp when pCR achieved. Need early dx & universal access to HER2 drugs in LMICs. doi.org/10.1200/GO-24-… #GlobalOnc

ACTREC_TMC's tweet image. Indian real-world data (@JCOGO_ASCO) confirms trastuzumab before/after surgery + maintenance enhances survival in HER2-positive breast cancer, esp when pCR achieved. 

Need early dx & universal access to HER2 drugs in LMICs. 

doi.org/10.1200/GO-24-… 

#GlobalOnc

Gef vs Gef plus Pemetrexed & Carboplatin Chemotherapy in EGFR-Variant Lung Cancer—Long-Term Results of a Randomized Clinical Trial A paper very close to our hearts, true reflection of the hard work of our solid unit 2 department. jamanetwork.com/journals/jamao… jamanetwork.com/journals/jamao…


Minit Shah сделал(а) репост

Neoadjuvant chemotherapy in locally advanced Sinonasal Teratocarcinosa... sciencedirect.com/science/articl… @DrVijayPatil11 @VanitaNoronha @minitjshah


A much awaited answer from our Solid Tumour Unit 2 group at Tata Memorial Center. Congratulations Dr Vanita, Dr Vijay, Dr Kumar sir and the entire Solid Tumour Unit 2 team!!!! ejcancer.com/article/S0959-…


Minit Shah сделал(а) репост

Parween et al. present a pan-cancer analysis of homologous recombination DNA repair pathway genes in the Indian population. Read here: bit.ly/3GXbtvh #CancerResearch #CRST #Oncology #DNA #MedTwitter

CRSTonline's tweet image. Parween et al. present a pan-cancer analysis of homologous recombination DNA repair pathway genes in the Indian population. Read here: bit.ly/3GXbtvh
#CancerResearch #CRST #Oncology #DNA #MedTwitter
CRSTonline's tweet image. Parween et al. present a pan-cancer analysis of homologous recombination DNA repair pathway genes in the Indian population. Read here: bit.ly/3GXbtvh
#CancerResearch #CRST #Oncology #DNA #MedTwitter
CRSTonline's tweet image. Parween et al. present a pan-cancer analysis of homologous recombination DNA repair pathway genes in the Indian population. Read here: bit.ly/3GXbtvh
#CancerResearch #CRST #Oncology #DNA #MedTwitter

Minit Shah сделал(а) репост

So proud of the junior most member of our team at @TataMemorial- Dr Minit Shah. Thanks @EvelynWongYT for highlighting this. @Nandinimenon18 @DrVijayPatil11 @ajaysinghmedonc @tmhmedoncalumni @KNJobanputra

Impressive discussion on Inequities in Access to Standards of Cancer Care, using India as an case example by Dr Minit Jalan Shah. - did you know that @TataMemorial was built in record time 10 months!!! #esmoasia23

EvelynWongYT's tweet image. Impressive discussion on Inequities in Access to Standards of Cancer Care, using India as an case example by Dr Minit Jalan Shah. - did you know that @TataMemorial was built in record time 10 months!!! #esmoasia23
EvelynWongYT's tweet image. Impressive discussion on Inequities in Access to Standards of Cancer Care, using India as an case example by Dr Minit Jalan Shah. - did you know that @TataMemorial was built in record time 10 months!!! #esmoasia23
EvelynWongYT's tweet image. Impressive discussion on Inequities in Access to Standards of Cancer Care, using India as an case example by Dr Minit Jalan Shah. - did you know that @TataMemorial was built in record time 10 months!!! #esmoasia23
EvelynWongYT's tweet image. Impressive discussion on Inequities in Access to Standards of Cancer Care, using India as an case example by Dr Minit Jalan Shah. - did you know that @TataMemorial was built in record time 10 months!!! #esmoasia23


Minit Shah сделал(а) репост

Impressive discussion on Inequities in Access to Standards of Cancer Care, using India as an case example by Dr Minit Jalan Shah. - did you know that @TataMemorial was built in record time 10 months!!! #esmoasia23

EvelynWongYT's tweet image. Impressive discussion on Inequities in Access to Standards of Cancer Care, using India as an case example by Dr Minit Jalan Shah. - did you know that @TataMemorial was built in record time 10 months!!! #esmoasia23
EvelynWongYT's tweet image. Impressive discussion on Inequities in Access to Standards of Cancer Care, using India as an case example by Dr Minit Jalan Shah. - did you know that @TataMemorial was built in record time 10 months!!! #esmoasia23
EvelynWongYT's tweet image. Impressive discussion on Inequities in Access to Standards of Cancer Care, using India as an case example by Dr Minit Jalan Shah. - did you know that @TataMemorial was built in record time 10 months!!! #esmoasia23
EvelynWongYT's tweet image. Impressive discussion on Inequities in Access to Standards of Cancer Care, using India as an case example by Dr Minit Jalan Shah. - did you know that @TataMemorial was built in record time 10 months!!! #esmoasia23

Minit Shah сделал(а) репост

Long term outcomes of phase I/II study of palliative triple metronomic... sciencedirect.com/science/articl… @DrVijayPatil11


Minit Shah сделал(а) репост

Metrnomic adjuvant after definitive CTRT in HNSCC is it usefull? Read our phase 3 study for the answer. @VanitaNoronha @AnticancerOrgUK @Nandinimenon18 @H_N_C_I_G @DrEzraCohen @DrHaddadRobert @docdcruz @drprathameshpai @venkymd @ashayoncology sciencedirect.com/science/articl…


United States Тренды

Loading...

Something went wrong.


Something went wrong.